{"schema_version":"secwatch.filing_event.v1","accession":"0001653477-24-000055","form_type":"8-K","ticker":"NGVT","cik":"0001653477","company_name":"Ingevity Corp","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.442003+00:00","generated_at":"2026-06-03T02:57:40.703099+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ingevity Q1 2024 net loss of $56M, sales down 13%; reiterates full-year guidance","bullets":["Net sales $340.1M, down 13% YoY; net loss $56.0M ($1.54 diluted EPS loss).","Adjusted earnings $19.1M, adjusted EPS $0.52; adjusted EBITDA $76.9M (22.6% margin).","Operating cash flow negative $12.1M, free cash flow negative $28.7M, including $19.8M cash losses on CTO resales.","Realized $20M cost savings in Q1; targeting $65-75M for full year 2024.","Full-year 2024 guidance reaffirmed: sales $1.40B-$1.55B, adjusted EBITDA $365M-$390M."],"urls":{"canonical":"https://secwatch.observer/filing/0001653477-24-000055","json":"https://secwatch.observer/filing/0001653477-24-000055.json","markdown":"https://secwatch.observer/filing/0001653477-24-000055.md","text":"https://secwatch.observer/filing/0001653477-24-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653477/000165347724000055/0001653477-24-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653477/000165347724000055/ngvt-20240501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T02:57:40.703099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7bfd5aa232728fe2053ba413b60517649c24104c","claim":"Ingevity Corp reported the three months ended March 31, 2024 results: revenue $340.1 million, net income Net loss of $56.0 million and diluted loss per share (EPS) of $1.54; adjusted earnings of $19.1 million and diluted adju. Guidance reaffirmed.","evidence_excerpt":"John E. Nypaver, Jr. 843-740-2002 investors@ingevity.com Ingevity reports first quarter 2024 financial results HIGHLIGHTS : (comparisons versus prior year period) • Net sales of $340.1 million, down 13% primarily as a result of the repositioning of Performance Chemicals • Net loss of $56.0 million and diluted loss per share (EPS) of $1.54; adjusted earnings of $19.1","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1653477/000165347724000055/0001653477-24-000055-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$340.1 million"},{"label":"Net income","value":"Net loss of $56.0 million and diluted loss per share (EPS) of $1.54; adjusted earnings of $19.1 million and diluted adju"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}